Background: Hysterectomy plus salpingo-oophorectomy represents the standard treatment for patients with well-differentiated endometrial cancer (EC) limited to the endometrium. It is estimated that over 5% of EC are diagnosed in nulliparous women aged 35-44 years. In addition, EC can affect obese women with diabetes, hypertension and other comorbidities increasing the surgical risk. Methods: This article reviews the English literature in PubMed regarding hormonal treatment of EC. Results: Use of hormonal therapies has resulted in complete remission in 60-70%; many of these women were able to achieve full-term pregnancies, and in case of contraindication to surgery, resection could be avoided. Several topics, however, such as patient selection, interobserver histologic evaluation, the type/duration of hormonal treatment, modality of evaluation before treatment and surveillance after treatment, which are still subject to controversy, are therefore discussed in this paper. Conclusion: Uterus-sparing treatment of well-differentiated EC limited to the endometrium is feasible and has acceptable efficacy in women with increased surgical risk or those who wish to preserve their fertility. Although the methods applied to determine disease extent beyond the endometrium are still unsatisfactory, patient selection is a crucial factor determining the outcome of treatment. However, women must be fully informed about the possibility of treatment failure and the necessity of a close follow-up after therapy.

Keywords:
Fertility sparing, High surgical risk, Hysteroscopy, Levonorgestrel intrauterine device, Medroxyprogesterone acetate, Megestrol acetate, Tumor resection, Well-differentiated endometrial carcinoma, Young patients
1.
International Agency for Research on Cancer. http://www-dep.iarc.fr (accessed February 1, 2011).
2.
Ries LAG, Melbert D, Krapcho M, et al (eds): SEER Cancer Statistics Review, 1975-2005, Bethesda, National Cancer Institute, 2009.
3.
Randall TC, Kurman RJ: Progestin treatment of atypical hyperplasia and well-differentiated carcinoma of the endometrium in women under age 40. Obstet Gynecol 1997;90:434-440.
4.
Chiva de Agustín L, Lapuente Sastre F, Corraliza Galán V, et al: Conservative management of patients with early endometrial carcinoma: a systematic review. Clin Trans Oncol 2008;10:155-162.
5.
Ramirez PT, Frumovitz M, Bodurka DC, et al: Hormonal therapy for the management of grade 1 endometrial adenocarcinoma: a literature review. Gynecol Oncol 2004;95:133-138.
6.
Minig L, Franchi D, Boveri S, et al: Progestin intrauterine device and GnRH analogue for uterus-sparing treatment of endometrial precancers and well-differentiated early endometrial carcinoma in young women. Ann Oncol 2011;22:643-649.
7.
Mazzon I, Corrado G, Masciullo V, et al: Conservative surgical management of stage IA endometrial carcinoma for fertility preservation. Fertil Steril 2010;93:1286-1289.
8.
Tangjitgamol S, Manusirivithaya S, Hanprasertpong J: Fertility-sparing in endometrial cancer. Gynecol Obstet Invest 2009;67:250-268.
9.
Trimble CL, Kauderer J, Zaino R, et al: Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study. Cancer 2006;106:812-819.
10.
Horowitz NS, Dehdashti F, Herzog TJ, et al: Prospective evaluation of FDG-PET for detecting pelvic and para-aortic lymph node metastasis in uterine corpus cancer. Gynecol Oncol 2004;95:546-551.
11.
Laurelli G, Di Vagno G, Scaffa C, et al: Conservative treatment of early endometrial cancer: preliminary results of a pilot study. Gynecol Oncol 2011;120:43-46.
12.
Zaino R, Kauderer J, Liu Trimble C, et al: Reproducibility of the diagnosis of atypical endometrial hyperplasia. Cancer 2006;106:804-811.
13.
International Society of Gynaecological Pathologists (ISGP), World Health Organization (WHO). Classification of endometrial hyperplasia; in Kurman RJ (ed): Blaustein's Pathology of the Female Genital Tract, ed 5. Berlin, Springer, 2002, pp 467-500.
14.
Kurman RJ, Norris HJ: Evaluation of criteria for distinguishing atypical endometrial hyperplasia from well-differentiated carcinoma. Cancer 1982;49:2547-2559.
15.
Harvard Medical School/Brigham and Women's Hospital: Endometrium.org. www.endometrium.org (accessed February 1, 2011).
16.
Gotlieb WH, Beiner ME, Shalmon B, et al: Outcome of fertility-sparing treatment with progestins in young patients with endometrial cancer. Obstet Gynecol 2003;102:718-725.
17.
Creasman WT: Prognostic significance of hormone receptors in endometrial cancer. Cancer 1993;71:1467-1470.
18.
Ota T, Yoshida M, Kimura M, et al: Clinicopathologic study of uterine endometrial cancinoma in young women aged 40 years and younger. Int J Gynecol Cancer 2005;15:657-662.
19.
Niwa K, Tagami K, Lian Z, et al: Outcome of fertility-preserving treatment in young women with endometrial carcinomas. BJOG 2005;112:317-320.
20.
Wang CB, Wang CJ, Chou HH, et al: Fertility-preserving treatment in young patients with endometrial adenocarcinoma. Cancer 2002;94:2192-2198.
21.
Dhar K, NeedhiRajan T, Koslowski M, et al: Is levonorgestrel intrauterine system effective for treatment of early endometrial cancer? Report of four cases and review of the literature. Gynecol Oncol 2005;97:924-927.
22.
Takeshima N, Hirai Y, Yano K, et al: Ovarian metastasis in endometrial carcinoma. Gynecol Oncol 1998;70:183-187.
23.
Frumovitz M, Gerhenson D: Fertility-sparing therapy for young women with endometrial cancer. Expert Rev Anticancer Ther 2006;6:27-32.
24.
Savelli L, Ceccarini M, Ludovisi M, et al: Preoperative local staging of endometrial cancer: transvaginal sonography vs magnetic resonance imaging. Ultrasound Obstet Gynecol 2008;31:560-566.
25.
Creasman WT, Morrow CP, Bundy BN, et al: Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Group Study. Cancer 1987;60:2035-2041.
26.
Imai M, Jobo T, Sato R, et al: Medroxyprogesterone acetate therapy for patients with adenocarcinoma of the endometrium who wish to preserve the uterus - usefulness and limitations. Eur J Gynaecol Oncol 2001;22:217-220.
27.
Zerbe MJ, Bristow R, Grumbine FC, et al: Inability of preoperative computed tomography scans to accurately predict the extent of myometrial invasion and extracorporal spread in endometrial cancer. Gynecol Oncol 2000;78:67-70.
28.
Evans-Metcalf ER, Brooks SE, Reale FR, et al: Profile of women 45 years of age and younger with endometrial cancer. Obstet Gynecol 1998;91:349-354.
29.
Walsh C, Holschneider C, Hoang Y, et al: Coexisting ovarian malignancy in young women with endometrial cancer. Obstet Gynecol 2005;106:693-699.
30.
Morice P, Fourchotte V, Sideris L, et al: A need for laparoscopic evaluation of patients with endometrial carcinoma selected for conservative treatment. Gynecol Oncol 2005;96:245-248.
31.
Gadducci A, Spirito N, Baroni E, et al: The fertility-sparing treatment in patients with endometrial atypical hyperplasia and early endometrial cancer: a debated therapeutic option. Gynecol Endocrinol 2009;25:683-691.
32.
Vereide AB, Kaino T, Sager G, et al: Bcl-2, BAX, and apoptosis in endometrial hyperplasia after high dose gestagen therapy: a comparison of responses in patients treated with intrauterine levonorgestrel and systemic medroxyprogesterone. Gynecol Oncol 2005;97:740-750.
33.
Signorelli M, Caspani G, Bonazzi C, et al: Fertility-sparing treatment in young women with endometrial cancer or atypical complex hyperplasia: a prospective single-institution experience of 21 cases. BJOG 2009;116:114-118.
34.
Wang SJ, Sakamoto T, Yasuda Si S, et al: The relationship between telomere length and telomerase activity in gynecologic cancers. Gynecol Oncol 2002;84:81-84.
35.
Mutter GL, Lin MC, Fitzgerald JT, et al: Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst 2000;92:924-930.
36.
Faquin WC, Fitzgerald JT, Boynton KA, et al: Intratumoral genetic heterogeneity and progression of endometrioid type endometrial adenocarcinomas. Gynecol Oncol 2000;78:152-157.
37.
Mutter GL, Baak JP, Crum CP, et al: Endometrial precancer diagnosis by histopathology, clonal analysis, and computerized morphometry. J Pathol 2000;190:462-469.
38.
Gotlieb W, Beiner M, Shalmon B, et al: Outcome of fertility-sparing treatment with progestins in young patients with endometrial cancer. Obstet Gynecol 2002;102:718-725.
39.
Gruber SB, Thompson WD: A population-based study of endometrial cancer and familial risk in younger women. Cancer and Steroid Hormone Study Group. Cancer Epidemiol Biomarkers Prev 1996;5:411-417.
40.
Vasen HF, Wijnen JT, Menko FH, et al: Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. Gastroenterology 1996;110:1020-1027, erratum 1402.
41.
Boks DE, Trujillo AP, Voogd AC, et al: Survival analysis of endometrial carcinoma associated with hereditary nonpolyposis colorectal cancer. Int J Cancer 2002;102:198-200.
42.
Montz FJ, Bristow BE, Bovicelli A, et al: Intrauterine progesterone treatment of early endometrial cancer. Am J Obstet Gynecol 2002;186:651-657.
43.
Bahamondes L, Ribeiro-Huguet P, de Andrade KC, et al: Levonorgestrel-releasing intrauterine system (Mirena) as a therapy for endometrial hyperplasia and carcinoma. Acta Obstet Gynecol Scand 2003;82:580-582.
44.
Giannopoulos T, Butler-Manuel S, Tailor A: Levonorgestrel-releasing intrauterine system (LNG-IUS) as a therapy for endometrial carcinoma. Gynecol Oncol 2004;95:762-764.
45.
Dhar K, NeedhiRajan T, Koslowski M, et al: Is levonorgestrel intrauterine system effective for treatment of early endometrial cancer? Report of four cases and review of the literature. Gynecol Oncol 2005;97:924-927.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.